Summary Overexpression of the epidermal growth factor receptor (EGFR) and ErbB-2 has been observed in a variety of human tumours, making these receptors promising targets for directed tumour therapy. Since many tumour cells express both ErbB-2 and EGFR and these receptors synergise in cellular transformation, therapeutic reagents simultaneously binding to ErbB-2 and EGFR might offer advantages for tumour therapy. We have previously described the potent anti-tumoral activity of a bispecific antibody toxin that contains ErbB-2-and EGFR-specific single-chain Fv (scFv) domains. Here we report the construction and functional characterisation of a novel bispecific recombinant toxin, scFv(FRP5)-TGFa-ETA. The fusion protein consists of the antigen-binding domain of the ErbB-2-specific MAb, FRP5, and the natural EGFR ligand, TGFa, inserted at different positions in truncated Pseudomonas exotoxin A. ScFv(FRP5)-TGFa-ETA protein displayed binding to EGFR and ErbB-2, thereby inducing activation of the receptors, which was dependent on the cellular context and the level of EGFR and ErbB-2 expression. The bispecific molecule was cytotoxic in vitro for tumour cells expressing various levels of the target receptors. In vivo scFv(FRP5)-TGFoa-ETA potently inhibited the growth of established A431 tumour xenografts in nude mice.
Human tumours of epithelial origin often overexpress members of the ErbB/epidermal growth factor receptor (EGFR)-related family of receptor tyrosine kinases. This receptor family comprises ErbB/EGFR, Neu/ErbB-2, ErbB-3 and ErbB-4 (reviewed in Peles and Yarden, 1993) . In particular, overexpression of EGFR and ErbB-2 has been shown to contribute directly to malignancy (reviewed in Gullick, 1991; Hynes and Stern, 1994) . Owing to their aberrant expression on tumour cells and their accessibility from the extracellular space, these receptors are suitable targets for directed cytotoxic therapy. Several recombinant toxins have been described which consist of a target cell recognition domain with specificity for EGFR or ErbB-2 genetically fused to the enzymatic domain of the bacterial Pseudomonas exotoxin A (ETA). TGFa-PE40, a toxin fusion protein carrying at the N-terminus the natural EGFR ligand transforming growth factor (TGF) o, is cytotoxic for EGFRexpressing tumour cells in vitro and in in vivo models of human cancer (Pai et al., 1991) . Anti-tumour activity of this protein has recently been demonstrated in a phase I study in a subset of patients with superficial bladder cancer (Goldberg et al., 1995) . A similar ETA fusion protein containing as a target cell recognition domain a recombinant single-chain Fv(scFv) fragment derived from EGFR-specific monoclonal antibody (MAb) 225 (Kawamoto et al., 1983 ) displayed cytotoxic activity in vitro and in animal models in vivo which was highly selective for human tumour cells overexpressing EGFR (Wels et al., 1995) . No natural ligand is available which binds ErbB-2 directly. Therefore, recombinant fragments of ErbB-2-specific MAbs have been employed to direct target cell specificity. ScFv-ETA fusion proteins containing ErbB-2-specific binding domains have demonstrated highly selective anti-tumour activity in vitro and in vivo (Wels et al., , 1995 Batra et al., 1992) .
EGFR and ErbB-2 are often coexpressed in human tumours. ErbB receptor tyrosine kinases undergo activation after ligand binding and receptor dimerisation. Both the EGFR ligand EGF as well as the ErbB-3 and ErbB-4 ligand neu differentiation factor/heregulin, in addition to activation of their cognate receptors, also induce ErbB-2 phosphorylation, most likely via ligand-induced heterodimerisation and cross-phosphorylation (King et al., 1988; Plowman et al., 1993; Sliwkowski et al., 1994) . In experimental models coexpression of ErbB-2/Neu and EGFR leads to the synergistic transformation of cells (Kokai et al., 1989) , suggesting a role for receptor interaction in the development of human malignancies. The anti-tumour activity of recombinant toxins was enhanced by concurrently targeting EGFR and ErbB-2. An additive cytotoxic effect has been observed upon simultaneous treatment of tumour cells coexpressing ErbB-2 and EGFR with the ErbB-2-specific and EGFR-specific antibody toxins scFv(FRP5)-ETA and scFv(225)-ETA (Wels et al., 1995) . Likewise, scFv2(FRP5/ 225)-ETA, a fusion toxin containing an ErbB-2-specific and an EGFR-specific antibody domain fused to ETA in a single polypeptide chain, was more potent than corresponding monospecific toxins in the killing of human tumour cells coexpressing ErbB-2 and EGFR in vitro and in vivo (Schmidt et al., 1996) .
Here we report the construction and functional characterisation of a recombinant bispecific single chain toxin, scFv(FRP5)-TGFa-ETA, containing a scFv antibody domain specific for ErbB-2 and the EGFR ligand TGFoa linked to Pseudomonas exotoxin A. The fusion protein displayed specific binding to ErbB-2 and EGFR resulting in the activation of the kinase domains of both receptors. ScFv(FRP5)-TGFx-ETA was cytotoxic in vitro for human tumour cells expressing ErbB-2, EGFR or both target antigens and displayed potent anti-tumour activity on established A431 tumours in a nude mouse tumour model in vivo. al., 1995) , resulting in the expression plasmid pSW202-TGFa encoding a fusion protein of amino acids 1-50 of human TGFa and exotoxin A (ETA) amino acids 252 to 613 (TGFa-ETA).
Materials and methods

Cell lines
A Sacd restriction site was introduced into the exotoxin A gene 5' of the ETA codon 380 by PCR as described above using the plasmid pSW200 (Wels et al., 1995) as a template, and two oligonucleotides, complementary to a region in the ETA gene 5'-GCCGGGAGCTCTGCGGGCCCGGCGG-3', and complementary to the non-coding vector region 3' of the ETA gene insert in plasmid pSW200 5'-CTGTATCAGGCT-GAAAATCTTCTC-3' respectively. PCR products were digested with Sacd and BglII. The expected 814 bp Sacd! BglII ETA DNA fragment encoding amino acids 380-613 of ETA, the HindIII/SacI TGFoa cDNA fragment from the PCR described above and pSW50 vector (Wels et al., 1995) digested with HindIII/BglII were ligated. The resulting plasmid encoding a fusion of TGFa amino acids 1-50 and ETA amino acids 380-613 was digested with HindIII. A HindlIl fragment encoding the ErbB-2-specific scFv(FRP5) fused to amino acids 252-366 of ETA was derived from the expression plasmid pMS240-5-225 encoding the bispecific single chain antibody toxin scFv2 (FRP5/225)-ETA (Schmidt et al., 1996) , and inserted into the HindIII-digested TGFa-ETA380 613 encoding plasmid. The integrity of the resulting plasmid, pMS238-5-TGFa, encoding a fusion of scFv(FRP5), ETA amino acids 252-366, human TGFax amino acids 1-50 and ETA amino acids 380-613 (scFv(FRP5)-TGFcx-ETA) was confirmed by restriction analysis and DNA sequencing.
Bacterial expression and purification of mono-and bispecific single chain ETA fusion proteins Plasmids encoding recombinant mono-and bispecific fusion toxins were transformed into E coli CC1 18 (Wels et al., 1995) . Single colonies were grown overnight at 37°C in LB medium containing 0.6% glucose and 100 jMg ml -ampicillin. The biological activity of the TGFoa domain was determined via induction of EGFR and ErbB-2 activation. NEI (Beerli et al., 1994) , SKBR3, MDA-MB453 and A431 cells were grown for 16 in DMEM containing 0.5% FCS. Purified recombinant ETA fusion proteins were added at a concentration of 1 ,ig ml-' followed by incubation for 10 min at 37°C. Control cells were treated with PBS or 100 ng ml-' EGF. Cells were lysed in a buffer containing 50 mM Tris-HCl pH 7.5, 5 mM EGTA, 150 mM sodium chloride, 10 jug ml-' aprotinin, 10 ig ml-' leupeptin, 1 mM phenylmethylsulphonyl fluoride (PMSF), 2 mM sodium vanadate, 50 mM sodium fluoride, 50 mm sodium molybdate, 1% Triton X-100, 0.5% desoxycholate, 0.1% sodium dodecyl sulphate (SDS). Extracts were clarified by centrifugation at 10 000 g for 10 min at 4°C. Cleared cell lysates containing 15 Mg each of total proteins were applied on a 7.5% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS -PAGE). After electrophoresis proteins were blotted on a PVDF membrane (Millipore, Eschborn, Germany) and phosphotyrosine-containing proteins were detected by incubation of the membrane with an antiphosphotyrosine MAb as described , followed by incubation with an anti-mouse horseradish peroxidase-coupled antibody and chemiluminescent detection with the ECL kit (Amersham, Aylesbury, UK).
Cell viability assay The cell killing activity of ETA fusion proteins was measured basically as described Competition experiments A431 cells were used in a cell viability assay as described above. The cells were grown for 40 h in the presence of 100 ng ml-1 scFv(FRP5)-TGFa-ETA in the absence or presence of a 70-fold molar excess of MAbs FRP5, or 225, or a combination of the two MAbs as competitors. The relative amount of viable cells after treatment was determined as described above.
In vivo anti-tumour activity of scFv(FRP5)-TGFa-ETA In vivo anti-tumour activity of the scFv(FRP5)-TGFa-ETA and TGFax-ETA was tested using A431 squamous cell carcinoma xenografts in athymic nude mice as described (Schmidt et al., 1996) . Approximately 25 mg of tumour tissue was subcutaneously implanted in each mouse (5 mice per group). Starting on day 6 after implantation, when the tumour volume had reached approximately 100 mm3, the mice were treated for 10 days with intraperitoneal injections of 80 pmol of scFv(FRP5)-TGFa-ETA (5.8 jug) or TGFa-ETA (3.8 jug) twice daily. The control group received PBS. Tumour growth was followed by measuring two perpendicular tumour diameters, the tumour volumes were calculated and the data were statistically analysed.
Results
Construction and bacterial expression of TGFx-ETA and scFv(FRP5)-TGFa-ETA cDNA encoding amino acids 1 to 50 of TGFa was derived by reverse transcription of mRNA isolated from TGFaproducing MDA-MB468 human breast carcinoma cells and subsequent amplification by the polymerase chain reaction with specific oligonucleotide primers introducing restriction sites at the 5' and 3' ends of the cDNA. A monovalent fusion of TGFc with truncated Pseudomonas exotoxin A, lacking the original cell binding domain Ta of the toxin, was constructed by introducing the TGFa cDNA fragment 5' of the ETA gene in the previously described expression plasmid pSW202 (Wels et al., 1995) . The resulting plasmid was designated pSW202-TGFa and encodes a protein very similar to the previously described TGFcx-PE40 (Siegall et al., 1989) . A bivalent fusion containing the ErbB-2-specific single chain antibody scFv(FRP5), ETA amino acids 252-366, TGFa and ETA amino acids 380-613, was constructed as described in detail in Materials and methods by stepwise assembly of DNA fragments encoding scFv(FRP5)-ETA252 366 (Schmidt et al., 1996) , TGFa and ETA380 613 in the expression plasmid pSW50 (Wels et al., 1995) . The resulting expression plasmids, pSW202-TGFax encoding monovalent TGFc-ETA and pMS238-5-TGFae encoding the bivalent scFv(FRP5)-TGFoc-ETA, contain an IPTG-inducible tac promoter followed by sequences encoding the ompA signal peptide, the synthetic FLAG epitope, six His residues, followed in the case of TGFa-ETA by TGFoa, six His residues and ETA amino acids 252-613 or, in the case of scFv (FRP5) al., 1992, 1995) were expressed in E. coli and purified as described in Materials and methods. SDS-PAGE analysis of the purified material revealed a purity of greater than 70% after a single round of Ni2" affinity purification (Figure Ib) .
Binding properties of scFv(FRP5)-TGFx-ETA The recombinant scFv(FRP5)-TGFa-ETA was tested for its ability to bind to human ErbB-2 in ELISA experiments. The bivalent scFv(FRP5)-TGFa-ETA at concentrations of 1 and 10 nM was added to the wells of 96-well plates coated with purified recombinant extracellular domain of ErbB-2, the plates were incubated at 37°C for 1 h and specifically bound protein was determined. The monovalent ErbB-2-specific fusion protein scFv(FRP5)-ETA (Wels et al., , 1995 and EGFR-specific TGFa-ETA served as controls. The results are shown in Figure 2a . Both the bivalent scFv(FRP5)-TGFa-ETA and the monovalent scFv(FRP5)-ETA bound specifically to recombinant ErbB-2, whereas no specific binding of the growth factor toxin TGFa-ETA was observed.
The ability of the TGFa-containing toxins, scFv(FRP5)-TGFax-ETA and TGFa-ETA, to bind to and activate EGFR was tested on NEl murine fibroblasts expressing human EGFR cDNA (Beerli et al., 1994) . NEl cells were treated for 10 min at 37°C with the bivalent scFv(FRP5)-TGFa-ETA, or the monovalent TGFa-ETA and scFv(FRP5)-ETA. Control cells were treated with PBS or 100 ng ml-' EGF. Equal amounts of cell lysates were assayed for their phosphotyrosine content by SDS-PAGE and subsequent immunoblotting with a specific anti-phosphotyrosine antibody . The results are shown in Figure 2b . Treatment of cells with EGF (lane 2), TGFa-ETA (lane 4) or scFv(FRP5)-TGFa-ETA (lane 5) led to a strong increase in the phosphotyrosine content of a protein corresponding in size with the 170 kDa EGFR, which was confirmed by reprobing the filter with an anti-EGFR serum (Figure 2b, bottom) . PBS and the monovalent ErbB-2-specific scFv(FRP5)-ETA had no effect on the phosphotyrosine content of the receptor (lanes 1 and 3) . The results show that in contrast to the ErbB-2-specific antibody toxin scFv(FRP5)-ETA, the bivalent scFv(FRP5)-TGFo-ETA and the monovalent TGFoa-ETA bind to and activate EGFR.
In vitro cell killing activity of scFv(FRP5)-TGFax-ETA We tested the cell killing activity of the bispecific scFv(FRP5)-TGFa-ETA on human tumour cell lines expressing different levels of ErbB-2 and EGFR as shown in Table  I . A431 human squamous cell carcinoma cells and the human . The results are shown in Figure 3 and the IC50 values are summarised in Table I . ScFv(FRP5)-TGFa-ETA was cytotoxic for the five cell lines tested. The monospecific scFv(FRP5)-ETA and the bispecific scFv(FRP5)-TGFa-ETA showed similar activity on MDA-MB453 cells overexpressing ErbB-2. Both toxins displayed a greater than 50-fold higher cell killing activity than the EGFR-specific TGFx-ETA, with IC50 values of less than 0.01 nM vs 0.53 nM respectively. Similarly, T47D cells were more sensitive to the toxins containing the ErbB-2-specific scFv than they were to TGFa-ETA, with IC50 values of 0.13, 0.82 and 2.23 nm for scFv(FRP5)-ETA, scFv(FRP5)-TGFa-ETA and TGFa-ETA respectively. On A431 cells expressing high levels of EGFR and low levels of ErbB-2, scFv(FRP5)-TGFax-ETA was 13 times more active than scFv(FRP5)-ETA, but less active than TGFoa-ETA, with IC50 values of 0.04, 0.52 and less than 0.02 nM respectively. This is in contrast to another bivalent ETA fusion protein, scFv2(FRP5/225)-ETA, which contains two scFv domains specific for ErbB-2 and EGFR and was more active on A431 cells than either of the corresponding monospecific scFvtoxins (Schmidt et al., 1996, and Figure 6a . Treatment with both fusion toxins led to the inhibition of A431 tumour growth during treatment to a similar extent. By day 22, when the experiment was terminated, the size of the tumours in the scFv(FRP5)-TGFa-ETA and TGFa-ETA treated animals was, respectively, 21% and 22% of the tumour size in the control group. A transient weight loss of less than 10% was observed during the course of the TGFa-ETA treatment (Figure 6b ). Weight loss of less than 5% was observed in the scFv(FRP5)-TGFa-ETA-treated animals. All animals recovered quickly after the end of the treatment. 
Discussion
Overexpression of EGFR and ErbB-2 has been observed in a variety of human tumours making these receptors promising targets for directed tumour therapy (reviewed in Gullick, 1991; Hynes and Stern, 1994) . Several recombinant Pseudomonas exotoxin A fusion proteins binding to EGFR or ErbB-2 have been described (Chaudhary et al., 1987; Wels et al., 1992 Wels et al., , 1995 Batra et al., 1992) . Since many tumour cells express both ErbB-2 and EGFR, therapeutic reagents binding to both receptor proteins might offer advantages over monospecific molecules by inducing the formation of receptor heterodimers which in turn might lead to more rapid uptake of toxin-receptor complexes. We have recently characterised scFv2(FRP5/225)-ETA, a bispecific antibody toxin, which contains, in a single polypeptide chain, ErbB-2-and EGFR-specific scFv domains linked to Pseudomonas exotoxin A (Schmidt et al., 1996) . This molecule was cytotoxic in vitro and in vivo for tumour cells expressing EGFR, ErbB-2 or both receptor proteins.
Here (Hwang et al., 1987) . insertion of foreign protein sequences a boundaries. Although insertion at certain result in reduced cytotoxic activity, Pseudoi A has proved to be surprisingly flexible possible integration sites for small heterologous binding domains. ETA fusion proteins containing TGFa, either Nterminal of the ETA translocation domain II (Siegall et al., 1989) similar to TGFcx-ETA in our study, or at the Cterminus of the enzymatic domain III (Chaudhary et al., 1987) , have been derived and were biologically active. The activity of proteins with a heterologous binding domain inserted between domains II and III of ETA seems to be dependent upon the size and/or nature of the ligand. The 50 amino acid TGFa domain located between translocation and enzymatic domains in the bispecific scFv(FRP5)-TGFa-ETA retains binding activity, whereas the 27 kDa ErbB-2-specific scFv(FRP5) domain inserted at the same position results in a fusion toxin with drastically reduced cytotoxic activity (Schmidt and Wels, unpublished data).
Internalisation of toxin-receptor complexes and subsequent intracellular processing of the ETA domain is a prerequisite for the cytotoxic activity of recombinant fusion toxins (Ogata et al., 1992) . TGFa-containing growth factor toxins, but not the monospecific antibody toxins, scFv(FRP5)-ETA (anti-ErbB-2) and scFv(225)-ETA (anti-EGFR), activate ErbB-2 or EGFR upon binding, suggesting that the scFv-ETA proteins cannot induce receptor dimerisation and activation (Schmidt et al., 1996) . Cellular uptake of these antibody toxins therefore is dependent on the intrinsic turnover rate of the target receptors. In contrast, bispecific scFv(FRP5)-TGFa-ETA induced tyrosine phosphorylation of both EGFR and ErbB-2. Activation of the receptors upon binding might also result in more rapid internalisation of the bispecific toxin. Since activation of ErbB-2 and EGFR to a similar degree was also observed after treatment of A431 and SKBR3 cells with monospecific TGFa-ETA and EGF, it remains unclear to what extent EGFR/ErbB-2 heterodimerisation and activation in these cells is dependent on the additional ErbB-2-specific scFv domain in the bispecific molecule. In agreement with a previous report (Jeschke et al., 1995) (Real et al., 1986) . Systemic treatment of mice with high doses of TGFx-PE40, a fusion toxin very similar to the TGFxz-ETA used in this study, resulted in fatal liver damage, thus limiting the amount of toxin which could be applied safely (Pai et al., 1991) . In order to avoid systemic toxicity in a recent clinical study of TGFx-PE40 (TP40) in superficial bladder cancer, the molecule was applied directly into the bladder by transurethral instilation (Goldberg et al., 1995 
